Document Type and Number:
Japanese Patent JPWO2022054796
Kind Code:
A1
Abstract:
The present invention provides a biomarker for predicting response to cancer treatment and a method of using the biomarker. The present invention provides a method wherein the composition of a subpopulation of cells in a sample, said sample being obtained from a subject, is used as an indicator for predicting response to cancer treatment in the subject. The responses to cancer treatment in the subject can be predicted by comparing, to a reference value, the amount of CCR4-CCR6+ cell subpopulation in CD4+ T cell population of the subject.
Application Number:
JP2022517281A
Publication Date:
March 17, 2022
Filing Date:
September 07, 2021
Export Citation:
Domestic Patent References:
| JP2020512530A | 2020-04-23 |
Foreign References:
| WO2020171138A1 | 2020-08-27 |
Other References:
ANNA J. LOMAX: "Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors:", INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, vol. 20, no. 9, JPN6022019655, 8 May 2017 (2017-05-08), pages 1277 - 1285, XP055911592, ISSN: 0004777018, DOI: 10.1111/1756-185X.13076
各務 博, 新規免疫学的バイオマーカーを用いた画期的免疫チェックポイント阻害治療の開発, JPN6022019656, 27 December 2021 (2021-12-27), ISSN: 0004777019
各務 博, 新規免疫学的バイオマーカーを用いた画期的免疫チェックポイント阻害治療の開発, JPN6022019656, 27 December 2021 (2021-12-27), ISSN: 0004777019